John Parkinson

The company’s 15-valent conjugate shot becomes the first one that is approved in nearly a decade.

Studies, advances, and authorizations continue in this paramount area within infectious disease.

The CDC director endorsed the vote, and vaccines could be available to this young pediatric population by later this week.

The committee voted twice splitting the questions into younger children (6-11 years) and adolescent (12-17 years) cohorts due to different vaccine dosing amounts.

Aethlon Medical’s proprietary Hemopurifier is being studied to treat COVID-19, and they recently reported results.

The start of Men’s Health Week offers an opportunity for men to get screened for a variety of health issues and be proactive with their health including those who might be at risk of HIV and may benefit from PrEP.

Data results from its phase 3 trial showed it was statistically significant and the company plans to follow-up with regulatory bodies later this year.

Tecovirimat (Tpoxx) is an antiviral agent that is already indicated for another orthopoxvirus, smallpox. And studies are ongoing to see if it has potential efficacy in treating monkeypox.

The vote was 21-0 in favor of an emergency use authorization (EUA), with one voter abstaining.

The advisory group is meeting on Tuesday to discuss the vaccine’s presenting data and a potential authorization.

Although underutilized, this highly efficacious vaccine can help prevent numerous cancers including the most prevalent—head and neck and cervical cancers.

The organization is behind community-based funding and educational programs to propel a healthier society at a grassroots level.

A clinician discusses the disease burden of reoccurring CDI, but sees a silver lining in the new investigational therapies potentially changing the treatment paradigm for the better.

A clinician is advocating for incorporating diagnostic stewardship practices within antimicrobial stewardship programs, which could someday lead to best practice guidelines on a larger scale.

Utilizing a newer technology, investigators wanted to see if a reduction in time led to clinically significant antimicrobial adjustments.

A multicenter study looked at treating these infections with omadacycline.

A medical center wanted to review prescribing and documentation practices for their pharmacists.

With limitations on fidaxomicin at their facility, a hospital looked at vancomycin usage to determine if they needed to align with the new IDSA/SHEA CDI treatment guideline.

New information suggests a few more cases have surfaced in the United States, pending CDC confirmation.

A team of investigators studied Clostridioides difficile infection (CDI) isolates to gauge resistance in the 2 antibiotics.

The company issued the voluntary action due to potential salmonella contamination concerns.

Companies say the 3 doses of their vaccine meet all immunobridging criteria required for the Emergency Use Authorization (EUA).

A health system piloted a program that explored having an infectious disease pharmacist aid in guiding treatment.

Investigators sought information on how the infection is treated in outpatient clinics

A study looked at the utilization of the technology with this antibiotic class in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).

AdventHealth Orlando studied a small number of these fungal isolates to examine treatment resistance patterns.

Tend, a startup company, has developed its Gut Microbiome Collect and Prep (CAP) to enable a standardized method for stool (microbiome) encapsulation for the procedure.

The company is utilizing this platform to address new COVID-19 variants, combination vaccines, and potentially prevent HIV.

Tetracycline-class antibiotic, omadacycline (Nuzyra), is FDA approved for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), and is also being studied for other potential indications.

The company's investigational vaccine, which is in a phase 3 study, is an example of its commitment to addressing these viruses.